The purpose of this Continuing Education presentation is to review current clinical guidelines for the management of fungal infections, highlight emerging literature on antifungal agents, and discuss how pharmacists can apply these updates to patient care. While bacterial infections are commonly encountered and well understood by pharmacists, fungal infections are less frequent and often require review of institutional protocols and tertiary references to ensure appropriate drug selection, dosing, and monitoring. This presentation will provide an overview of antifungal pharmacotherapy, review key microbiologic principles, and discuss therapeutic drug monitoring (TDM) practices at Duke Regional Hospital to support pharmacist education and stewardship efforts. A complex case involving Fusarium infection treated with fosmanogepix (a novel, first-in-class antifungal agent) will be presented. Fosmanogepix is not yet FDA approved but has shown broad-spectrum activity against resistant molds and yeasts through inhibition of the fungal enzyme Gwt1, a unique target not shared by existing antifungal classes. Data from the AEGIS trial, which evaluated fosmanogepix in invasive mold infections, will be discussed to illustrate its promising role in future antifungal therapy. The presentation will be held on January 19th and January 21st, 2026 at 02:30pm – 03:30pm.

This is a private course; this course is not taking additional attendees.